C2 Adamantanyl galactosylceramide (d18:1/2:0)

C2 Adamantanyl galactosylceramide (AdaGalCer) (d18:1/2:0) is a bioactive sphingolipid. C2 Adamantanyl galactosylceramide (d18:1/2:0) stimulates glucocerebrosidase activity in vitro. C2 Adamantanyl galactosylceramide (d18:1/2:0) inhibits microsomal LacCer and Gb3 synthase, and inhibits cell sulfatide synthesis. C2 Adamantanyl galactosylceramide (d18:1/2:0) reduces glucosylceramide (GlcCer) levels in normal and lysosomal storage disease (LSD) cells. C2 Adamantanyl galactosylceramide (d18:1/2:0) acts as a substrate for A4GALT and is able to lower Gb3 levels with an IC50 concentration of 40 μM in fabry disease cells[1][2].

Product Specifications

CAS Number

[574738-16-2]

Product Name Alternative

AdaGalCer (d18:1/2:0) ; Admantanyl galactosylceramide (d18:1/2:0) ; Admantanyl galCer (d18:1/2:0)

UNSPSC

12352005

Target

Glucosylceramide Synthase (GCS) ; Glycosidase; Glycosyltransferase

Related Pathways

Epigenetics; Metabolic Enzyme/Protease; Neuronal Signaling

Field of Research

Metabolic Disease

Smiles

OC[C@H]([C@@H]([C@@H]([C@H]1O)O)O)O[C@H]1OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(CC23CC4CC(CC(C4)C3)C2)=O

Molecular Formula

C36H63NO8

Molecular Weight

637.89

References & Citations

[1]Kamani M, et al. Adamantyl glycosphingolipids provide a new approach to the selective regulation of cellular glycosphingolipid metabolism. J Biol Chem. 2011 Jun 17;286 (24) :21413-26.|[2]Kok K, et al. Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions. Biomolecules. 2021 Feb 12;11 (2) :271.